A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Patients With Alport Syndrome

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Patients With Alport Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs RG 012 (Primary)
  • Indications Hereditary nephritis
  • Focus Adverse reactions; Proof of concept
  • Acronyms HERA
  • Sponsors Regulus Therapeutics
  • Most Recent Events

    • 12 Jun 2017 Status changed from active, no longer recruiting to recruiting according to a Regulus Therapeutics media release.
    • 12 Jun 2017 According to a Regulus Therapeutics media release, this trial has been modified to increase enrollment to 40 patients to improve its statistical power. Dose frequency has also been adjusted to once every other week.
    • 12 Jun 2017 Planned number of patients changed from 30 to 40 according to a Regulus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top